{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:13:15Z","timestamp":1794244395967,"version":"4.9.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Co-occurring substance use disorders (SUDs) among individuals with schizophrenia are a prevalent and complex psychiatric comorbidity, which is associated with increased symptom severity, worsened illness trajectory and high rates of treatment non-adherence. Recent evidence suggests that the use of long-acting injectable (LAI) antipsychotics may provide an effective treatment option for individuals with this dual-diagnosis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic review of the literature was conducted using the databases PubMed, PsychInfo and Google Scholar for English-language studies, investigating the use of LAIs in co-occurring schizophrenia and substance use disorders (SCZ-SUDs).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Eight reports [one case study (<jats:italic>n<\/jats:italic> = 1), one case series (<jats:italic>n<\/jats:italic> = 8), three open-label retrospective studies (<jats:italic>n<\/jats:italic> = 75), and three randomized controlled trials (<jats:italic>n<\/jats:italic> = 273)] investigated the use of LAI antipsychotics in 357 participants with SCZ-SUDs [alcohol use disorder: 5 studies, <jats:italic>n<\/jats:italic> = 282; cocaine use disorder: 5 studies, <jats:italic>n<\/jats:italic> = 85; amphetamine use disorder: 1 study, <jats:italic>n<\/jats:italic> = 1; cannabis use disorder: 3 studies, <jats:italic>n<\/jats:italic> = 160; opioid use disorder: 3 studies, <jats:italic>n<\/jats:italic> = 19; methylenedioxymethamphetamine (MDMA) use disorder: 2 studies, <jats:italic>n<\/jats:italic> = 9; ketamine use disorder: 1 study, <jats:italic>n<\/jats:italic> = 4] and were included in this systematic review. Findings indicate significant improvements in substance use related outcomes across 7 of 8 studies, while in 6 of 8 studies, significant improvements in psychopathology-related outcomes were reported.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> LAI antipsychotics may be an efficacious intervention option for the treatment of SCZ-SUDs. However, varying methodological rigor, generally small sample sizes and heterogeneity of samples, settings, substances of abuse, tested LAIs and comparators, as well as psychosocial cotreatments and level of reported detail across studies requires that these findings be considered preliminary and interpreted with caution. Further research is required to better understand the effects of LAIs among individuals with SCZ-SUDs.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.808002","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:56:07Z","timestamp":1639569367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Alexandria S.","family":"Coles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunja","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony P.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0004867412443900","article-title":"The impact of alcohol and illicit drugs on people with psychosis: the second Australian national survey of psychosis","volume":"46","author":"Moore","year":"2012","journal-title":"Aust N Z J Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajem.2021.06.022","article-title":"Predictors of clinical severity in subjects attending the emergency department for substance use: a ten-year cross-sectional study","volume":"49","author":"Covino","year":"2021","journal-title":"Am J Emerg Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/00952990.2016.1200592","article-title":"Treatment of substance use disorders in schizophrenia","volume":"43","author":"Bennett","year":"2017","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0706743717720196","article-title":"Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders","volume":"62","author":"Crockford","year":"2017","journal-title":"Can J Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euroneuro.2018.11.1105","article-title":"Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. a systematic review and meta-analysis","volume":"29","author":"Krause","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/14656566.2016.1114101","article-title":"Pharmacological treatment of schizophrenia with comorbid substance use disorder","volume":"17","author":"Azorin","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/01.nmd.0000165089.14736.bf","article-title":"Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol","volume":"193","author":"Sayers","year":"2005","journal-title":"J Nerv Ment Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.jcp.0000194624.07611.5e","article-title":"The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine depen- dence: a preliminary report","volume":"26","author":"Smelson","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine versus other antipsychotic for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"J Dual Diagnosis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","article-title":"Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone","volume":"60","author":"Green","year":"2003","journal-title":"Schizophr Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1521-0391.2014.12126.x","article-title":"Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use dis- orders: a randomized study","volume":"23","author":"Schnell","year":"2014","journal-title":"Am Addict."},{"key":"B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00213-003-1658-9","article-title":"Naltrexone augmentation of neuroleptic treatment in alcohol abus- ing patients with schizophrenia","volume":"172","author":"Petrakis","year":"2004","journal-title":"Psychopharmacology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/schbul\/sbl010","article-title":"Psychotic spectrum disor- ders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram","volume":"32","author":"Petrakis","year":"2006","journal-title":"Schizophr Bull."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis","volume":"178","author":"Ostuzzi","year":"2021","journal-title":"Am J Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"20r13272","DOI":"10.4088\/JCP.20r13272","article-title":"Outcomes of neuroleptic malignant syndrome with depot versusoral antipsychotics: a systematic review and pooled, patient-level analysis of 662 case reports","volume":"82","author":"Guinart","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/acps.13359","article-title":"A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome","volume":"144","author":"Guinart","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/schbul\/sbab062","article-title":"Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia Cohort","volume":"47","author":"Guinart","year":"2021","journal-title":"Schizophr Bull."},{"key":"B23","first-page":"15","article-title":"Risks versus benefits of different types of long-acting injectable antipsychotics","volume":"67","author":"McEvoy","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0740-5472(96)00161-4","article-title":"Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study","volume":"14","author":"Ohuoha","year":"1997","journal-title":"J Subst Abuse Treat."},{"key":"B25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/JCP.0000000000001087","article-title":"Long-acting injectable aripiprazole for a schizophrenic patient concomitant with stimulant use disorder","volume":"39","author":"Chen","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3109\/00952999809016902","article-title":"Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study","volume":"24","author":"Levin","year":"1998","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000068809","article-title":"Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study","volume":"9","author":"Soyka","year":"2003","journal-title":"Eur Addict Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40801-020-00178-8","article-title":"Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: a multicentre, observational study","volume":"7","author":"Szerman","year":"2020","journal-title":"Drugs Real World Outcomes."},{"key":"B29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/070674370605100808","article-title":"Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity","volume":"51","author":"Rubio","year":"2006","journal-title":"Can J Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4088\/JCP.13m08838","article-title":"Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder","volume":"76","author":"Green","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/NDT.S171002","article-title":"Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life","volume":"14","author":"Cuomo","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B32","volume-title":"Overcoming Addictions. Skills Training For People With Schizophrenia","author":"Roberts","year":"1999"},{"key":"B33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Ther Adv Psychopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1192\/apt.bp.114.013565","article-title":"Why are long-acting injectable antipsychotics still underused?","volume":"21","author":"Bosanac","year":"2015","journal-title":"BJPsych Advances."},{"key":"B35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/appy.12234","article-title":"Recommendations for the optimal care of patients with recent-onset psychosis in the A sia- Pacific region","volume":"8","author":"Lo","year":"2016","journal-title":"Asia-Pacific Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.808002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:56:10Z","timestamp":1639569370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.808002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":36,"alternative-id":["10.3389\/fpsyt.2021.808002"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.808002","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"808002"}}